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Abstract
Background: The aim of this study was firstly, to improve and validate a cerebrospinal fluid (CSF)
prefractionation method followed by two-dimensional electrophoresis (2-DE) and secondly, using
this strategy to investigate differences between the CSF proteome of frontotemporal dementia
(FTD) patients and controls. From each subject three ml of CSF was prefractionated using liquid
phase isoelectric focusing prior to 2-DE.
Results: With respect to protein recovery and purification potential, ethanol precipitation of the
prefractionated CSF sample was found superior, after testing several sample preparation methods.
The reproducibility of prefractionated CSF analyzed on 2-D gels was comparable to direct 2-DE
analysis of CSF. The protein spots on the prefractionated 2-D gels had an increased intensity,
indicating a higher protein concentration, compared to direct 2-D gels. Prefractionated 2-DE
analysis of FTD and control CSF showed that 26 protein spots were changed at least two fold.
Using mass spectrometry, 13 of these protein spots were identified, including retinol-binding
protein, Zn-α-2-glycoprotein, proapolipoproteinA1, β-2-microglobulin, transthyretin, albumin and
alloalbumin.
Conclusion:  The results suggest that the prefractionated 2-DE method can be useful for
enrichment of CSF proteins and may provide a new tool to investigate the pathology of
neurodegenerative diseases. This study confirmed reduced levels of retinol-binding protein and
revealed some new biomarker candidates for FTD.
Background
Frontotemporal dementia (FTD) accounts for up to 20%
of presenil dementia cases [1] and is, after Alzheimer's dis-
ease (AD), the second most common form of early onset
dementia (at age < 65 years) [2]. The clinical picture in
FTD is characterized mainly by changes in personality and
Published: 18 November 2004
Proteome Science 2004, 2:7 doi:10.1186/1477-5956-2-7
Received: 02 February 2004
Accepted: 18 November 2004
This article is available from: http://www.proteomesci.com/content/2/1/7
© 2004 Hansson et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Proteome Science 2004, 2:7 http://www.proteomesci.com/content/2/1/7
Page 2 of 11
(page number not for citation purposes)
social behavior, signs of disinhibition, lack of insight and
changes in eating preferences [1]. Memory disturbances,
which prevail in AD, may also be found in FTD but not
usually to the same extent [3]. Post-mortem pathological
examination reveals bilateral atrophy of the frontal and
anterior temporal lobes in FTD and the ventricular system
is sometimes widened frontally [4]. The histological find-
ings provide a basis for the division of FTD into various
subtypes. Neurofibrillary tangles, a prominent neuronal
accumulation of hyperphosphorylated and filamentous
forms of the microtubule associated protein tau, are
found in FTD with Parkinsonism linked to chromosome
17, the hereditary variant of FTD, caused by mutations in
the tau gene [5]. Another FTD variant, Pick's disease, is
characterized by the presence of neuronal inclusion bod-
ies called Pick bodies, containing filamentous tau and
ubiquitin aggregates. The most common type of FTD is
frontal lobe degeneration of non-Alzheimer type, which is
clinically indistinguishable from Pick's disease, and histo-
logically characterized by neuron loss and gliosis in the
absence of distinctive histopathology, such as neurofibril-
lary tangles or other intracellular inclusions [4].
The diagnosis of FTD is often difficult and would be
greatly enhanced by the use of disease specific neuro-
chemical markers [6]. Several neuro-specific proteins in
the cerebrospinal fluid (CSF) of FTD have been investi-
gated [7,8] and elevation of cytoskeleton markers such as
neurofilament light protein and tau have been found [7-
10]. In order to expand the search for diagnostic biomar-
kers, which would also lead to a better understanding of
the pathophysiological mechanisms of neurodegenera-
tion, two-dimensional electrophoresis (2-DE) investiga-
tions of the CSF have previously been performed [11-15].
2-DE can effectively separate several proteins and their
isoforms simultaneously and is a useful tool for identify-
ing quantitative and qualitative protein differences
between the diseased and normal state. Previous pro-
teomic studies by our group have shown for the first time
that several proteins involved in FTD pathology are not
effected in the CSF of AD patients and vise versa, thus
establishing a likely difference in the pathophysiological
mechanism between FTD and AD [11,12].
Some abundant proteins, for example albumin and
immunoglobulins, limit the total amount of CSF proteins
that can be loaded on the 2-D gel, resulting in difficulties
detecting low abundant proteins of CSF. By using liquid
phase isoelectric focusing (LP-IEF) as a prefractionation
step prior to 2-DE we have previously shown that less
abundant CSF proteins can be enriched, thus making
them more easily detected and identified by mass spec-
trometry (MS) [16]. The advantage of this method is that
a larger volume of CSF (3 ml) can be used as starting mate-
rial and that proteins outside the selected pH interval of
the 2-D gel can be excluded. For several years alternative
prefractionation methods prior to 2-DE have been
reported [17-22], each with its advantages and
disadvantages.
The aim of the present study was to improve the prefrac-
tionation procedure for individual CSF samples and to
determine its reproducibility. Moreover, the second aim
of this study was to apply the method and further explore
disease-influenced proteins in CSF from FTD patients
compared to controls.
Results
Preparation of prefractionated CSF samples prior to 2-DE
Several strategies to reduce impurities, i.e. salt and
ampholytes, of the prefractionated CSF samples were per-
formed including, trichloroacetic acid (TCA)-acetone pre-
cipitation, ethanol precipitation, chloroform/methanol/
water precipitation and, micro Bio-Spin desalting col-
umn. The protein pattern on the 2-D gels and protein
recovery from the different sample preparation methods
were compared to that of acetone precipitation, previ-
ously used prior to prefractionated 2-DE of CSF [16]. We
found that ethanol precipitation gave the best result and
allowed us to reduce the focusing time from 25 000 Vh to
20 000 Vh, as recommended by the Protean cell manufac-
turer. Evaluation of gels with ethanol precipitated sample
showed that the same protein spots were present, or even
a few more, with similar intensities as in the gels with the
acetone treated CSF-samples (figure 1a and 1b). Further-
more, the optimal ethanol concentration was tested
showing that a concentration of at least 70% ethanol was
sufficient to generate a total protein recovery, determined
by the RC DC protein assay (figure 1c). An ethanol con-
centration of 71.25% (3/4 95% ethanol and 1/4 sample)
was used in the subsequent studies.
Both TCA-acetone and chloroform/methanol/water pre-
cipitation substantially reduced the number of spots and
resulted in streaky 2-D gels (data not shown). The use of
biospin columns gave well-focused 2-D gels but several
protein spots were reduced or lost (data not shown).
Reproducibility of prefractionated and unfractionated CSF 
on 2-D gels
Four identical CSF samples were individually prefraction-
ated by LP-IEF. Fractions 6–9 (having a pH of 4.5–6.0)
were pooled and analyzed on pH 4–7 strips in four repli-
cates. Coefficients of variation (CVs) were calculated for
the protein spots quantities, determined by the PD-Quest
software, and a selection of 20 spots had CVs ranging
from 1–33% (15.4% ± 8.3%, mean ± SD) (Figure 2a). The
spots were selected to represent a broad range of proteins
present in each replicate, i.e. proteins of different molecu-
lar weights and isoelectric points (pIs), low, medium andProteome Science 2004, 2:7 http://www.proteomesci.com/content/2/1/7
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Comparison of different protein precipitation methods Figure 1
Comparison of different protein precipitation methods. a) 75% acetone precipitation and b) 70% ethanol precipitation 
of prefractionated SYPRO Ruby stained CSF proteins with pH 4.5–6.0, separated on IPG-strips, pH 4–7. The molecular weights 
(MW) are in kDa. c) The protein recovery as % of control (untreated CSF) after precipitation with indicated concentrations of 
ethanol and 75% acetone. The protein recovery was measured using the RC DC protein assay (Bio-Rad).
Reproducibility study of direct and prefractionated 2-DE of CSF on SYPRO Ruby stained 2-D gels Figure 2
Reproducibility study of direct and prefractionated 2-DE of CSF on SYPRO Ruby stained 2-D gels. a) Represents 
a standard 2-D gel image of prefractionated (using LP-IEF) CSF fractions with pH 4.5–6.0, separated on a pH 4–7 IPG-strip. 
Numbers represents the CVs of encircled protein spots from four individually prefractionated, identical CSF samples separated 
by 2-DE. The mean CV of the 20 marked spots is 14.6% ± 7.9% (mean ± SD). b) Represents a standard 2-D gel image of 
directly analysed (after acetone precipitation) CSF proteins, separated on a pH 4–7 IPG-strip. Numbers represents the CVs of 
encircled protein spots from four replicate gels. The mean CV of the 20 marked spots is 15.4% ± 8.3% (mean ± SD). Molecular 
weights (MW) are in kDa.
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high abundant proteins as well as different isoforms of the
same protein. The reproducibility of direct 2-DE of CSF,
using pH 4–7 gels, in four replicates was also determined
and the CVs of a similar selection of 20 spots ranged from
1–35% (14.6% ± 7.9%, mean ± SD) (Figure 2b).
Comparison of direct and prefractionated 2-DE
Comparison of direct and prefractionated 2-DE showed
that the prefractionated gels contained more spots with a
higher protein concentration (Figure 3). The spots in the
pH 3–6 and pH 5–8 gels in particular were increased in
both number and density after prefractionation.
A proteomic study comparing prefractionated CSF from 
FTD patients and control subjects
The prefractionated 2-DE method was used to screen for
changes in the CSF proteome of five FTD patients com-
pared to that of five non-dementia controls in the pH
intervals 3–6, 4–7, and 5–8 (Figure 4a,4b,4c).
Comparing the protein densities of the gels, 10 spots were
up regulated and 16 spots down regulated, at least two
fold, in FTD patients compared to non-dementia controls.
Increased proteins are marked with a square and
decreased with a circle (Figure 4a,4b,4c). Thirteen of the
protein spots, corresponding to 7 different proteins, were
identified by mass spectrometry (MS) Table 1). In the FTD
group the following protein spots were increased: One
isoform of Zn-α-2-glycoprotein (ZAG),
proapolipoproteinA1 (ProapoA1), β-2-microglobulin (β-
2-m) and two isoforms of transthyretin (TTR), while a
reduction was seen in four isoforms of serum albumin,
two isoforms of alloalbumin and retinol binding protein
(RBP), compared to controls (Table 1).
Discussion
In this study we present an improved method for
increased detection of CSF proteins by a combination of
LP-IEF and 2-DE, followed by SYPRO Ruby protein
Comparison of direct and prefractionated CSF on SYPRO Ruby stained 2-D gels Figure 3
Comparison of direct and prefractionated CSF on SYPRO Ruby stained 2-D gels. The upper figures represents 
standard images of direct 2-DE, and the lower figures represents prefractionated 2-DE. The pH interval of the IPG strips is 
denoted in the upper left corner of the gels and the pH range of the prefractionated CSF samples at the bottom of the gel 
images. Molecular weights (MW) are in kDa.
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staining and protein identification by mass spectrometry,
for investigation of protein differences in CSF of FTD
patients compared to controls. To our knowledge no
other prefractionation method combined with 2-DE has
so far been developed and evaluated for CSF proteins.
The study showed that the reproducibility of prefraction-
ated 2-D gels could be compared to that of direct 2-D gels,
indicating that the extra prefractionation step did not
introduce additional variation and could be reproduced
from sample to sample. The protein detection and quan-
titative reproducibility of Coomassie Brilliant Blue [23],
silver, [24,25] and SYPRO Ruby [26,27] staining of direct
2-DE gels has previously been described. In one SYPRO
Ruby study [26] the reproducibility of the quantification
of 20 proteins, selected to represent well matched proteins
Prefractionated CSF from FTD patients compared to non-demented controls Figure 4
Prefractionated CSF from FTD patients compared to non-demented controls. Protein densities increased (squares) 
or decreased (circles) at least two times in prefractionated FTD CSF, analyzed using SYPRO-Ruby stained 2-DE gels. The five 
FTD patients were 70.6 ± 5.6 (mean ± SD) year-of-age and the five non-demented controls were 59.2 ± 11.9 (mean ± SD) 
year-of-age. The numbers on the 2-D gel pattern correlate each identified protein to the data given in table 2. Molecular 
weights (MW) are in kDa. a) Fraction 2–5 with pH 1.5–4.5 was analysed using a pH 3–6 linear IPG-strip. b) Fraction 6–9 with 
pH 4.5–6.0 was analysed using pH 4–7 linear IPG-strip. c) Fraction 10–14 with pH 6.0–7.5 was analysed using pH 5–8 linear 
IPG-strip in the first dimension.
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of different molecular weight and intensity, from four rep-
licate gels, had CVs ranging from 3 to 33%. This is in
agreement with our findings using a similar selection of
20 proteins, where the prefractionated 2-DE CVs ranged
from 1–33% (mean 14.5%) and the direct 2-DE ranged
from 1–35% (mean 15.4%). Mainly very faint spots have
CVs in the higher range (Figure 2).
In addition to the high salt concentration of CSF (> 150
mmol/L), ampholytes are also introduced into the sample
in the prefractionation step, LP-IEF. We previously
reported that the focusing time in the first dimension of
prefractionated 2-DE had to be increased [16] probably
due to insufficient "clean up" of the sample by acetone
precipitation. Therefore, different "clean up" procedures
were tested. Precipitation using ethanol was found to be
most effective, keeping the number and intensity of the
protein spots constant and allowing us to reduce the
focusing time in the first dimension. We found that TCA-
acetone precipitation reduced the protein content of the
sample in agreement with a study of directly analyzed CSF
samples [13]. In contrast to the results of Yuan et al. [13]
a substantial loss of protein spots using the Bio-Spin col-
umn was found. The reason might be that proteins are
retained in the spin column to a higher degree in the pres-
ence of ampholytes (Servalytes), which are small charged
peptides. Ethanol precipitation of plasma samples has
previously been performed[28], showing that a concen-
tration of 66.6% ethanol was sufficient to precipitate 99%
of the proteins [28]. This is in agreement with our find-
ings, that 100% of CSF proteins are precipitated at ethanol
concentrations above 70%.
When comparing direct and prefractionated 2-DE it is evi-
dent that the prefractionated gels contain more spots,
with higher protein quantities. Thus, the CSF proteins are
enriched in the prefractionation step, simplifying their
identification by MS, as shown in our previous study [16].
CSF analysis on the pH 3–6 and pH 5–8 gels in particular
is improved by the prefractionation step, probably
because the amount of CSF proteins in these pH ranges,
without prefractionation, is rather low.
In order to widen our search for protein differences in the
CSF of FTD patients the improved prefractionated 2-DE
procedure was applied to CSF from five FTD patients and
five control subjects. 26 protein spots were changed at
least two fold and 13 of these protein spots, representing
seven different proteins, were identified as ZAG,
ProapoA1, β-2-m, TTR, RBP, serum albumin and alloalbu-
min. Our previous direct 2-DE study [12] of the FTD pro-
teome showed that 7 proteins were significantly altered
compared to controls, including granin like neuroendo-
crine precursor, apolipoprotein E, pigment epithelium
derived factor, RBP, haptoglobulin and albumin.
A reduced level of RBP was consistent between our two
studies, and in this case RBP was found reduced in both
the pH 4–7 and the pH 5–8 gels. In contrast, CSF analysis
of AD showed increased levels of one isoform of RBP [11],
indicating a different role of RBP in the pathology of AD
and FTD. RBP is synthesized by hepatic parenchymal cells,
after binding to its ligand retinol, the complex is secreted
into the circulation [29], where it further complexes with
the plasma protein TTR. CSF RBP concentration has been
Table 1: CSF proteins increased or decreased, at least two fold in FTD vs. control
Spot 
no.
Protein identity NCBI 
Acc. no.
Theor. Mw 
(kDa)
Theor.pI No. 
peptides 
matched
Seq. cov. 
(%)
Levels in 
FTD vs. 
control
FTD spot norm. 
density (mean ± 
SD)
Control spot 
norm. density 
(mean ± SD)
1 Zn-α-2-glycoprotein 141596 31.6 5.70 4 22 ↑ 42256 ± 7227 4189 ± 979
2 proapolipo- protein A1 178775 28.9 5.45 14 43 ↑ 11572 ± 10432 4575 ± 2309
3 retinol- binding protein 20141667 20.9 5.27 4 35 ↓ 3680 ± 1675 8131 ± 4857
4 serum albumin 113576 52.0 5.69 11 22 ↓ 1819 ± 1657 7272 ± 1812
5 serum albumin 113576 52.0 5.69 11 22 ↓ 2415 ± 964 7839 ± 1906
6 serum albumin 113576 66.0 5.69 12 20 ↓ 1003 ± 309 3098 ± 1428
7 serum albumin 113576 66.0 5.69 9 15 ↓ 1528 ± 587 4896 ± 2551
8 alloalbumin 178345 69.2 5.99 12 19 ↓ 1361 ± 530 7454 ± 1748
9 alloalbumin 178345 69.2 5.99 12 19 ↓ 2463 ± 806 8395 ± 1475
10 retinol-binding protein 20141667 20.9 5.27 4 35 ↓ 1744 ± 551 5871 ± 2040
11 transthyretin 339685 13.8 5.3 8 81 ↑ 45198 ± 26202 9149 ± 2685
12 transthyretin 339685 13.8 5.3 8 81 ↑ 303002 ± 72750 147732 ± 30928
13 β-2-microglobulin 4757826 12.9 5.77 5 46 ↑ 41938 ± 43510 12287 ± 3161
The proteins were identified by MALDI-MS. The spot numbers refer to those given in figure 4.Proteome Science 2004, 2:7 http://www.proteomesci.com/content/2/1/7
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shown to correlate to those of serum [30]. Serum RBP and
retinol have been found to be reduced during acute infec-
tion and the decrease is proportional to the extent of the
infection [31], suggesting that reduced RBP levels may
result from an inflammation in the FTD brain.
Brain TTR is exclusively produced, secreted and regulated
by the choroid plexus [32-34]. TTR makes up 25% of the
total CSF protein content [32] and even higher concentra-
tions exist during prenatal and early postnatal life, indicat-
ing an importance of the protein in CNS development
[35]. In this study, the levels of two isoforms of TTR were
increased in the CSF from FTD patients. To our knowl-
edge, the TTR levels of FTD CSF have not previously been
studied, but in AD the CSF levels were decreased in an
immunological study, not differentiating between TTR
isoforms [36]. In contrast, the direct 2-DE study of the AD
proteome [11] showed an increased level of TTR, but of a
more acidic isoform, compared to this study. This high-
lights the capacity of 2-DE to quantify specific isoforms.
One isoform of β-2-m was found increased in this study.
Other studies have shown that CSF β-2-m is elevated in
patients with various neurological diseases including AD
[11], infectious meningoencephalitis [37], neurosar-
coidosis [38] and AIDS dementia complex [39]. β-2-m
constitutes the non-covalently bound light chain of major
histocompatibility complex class I molecule (MHCI) [40].
The MHCI complex is expressed on the surface of all
nucleated cells and the association of β-2-m to the MHCI
transmembranal chain is an absolute requirement for the
antigenic presentation function of the complex [40]. It has
been proposed that conformational changes of the MHCI
complex, associated with cell injury, can be responsible
for increased shedding of β-2-m from the cell membranes
with consequent expansion of the circulating β-2-m pool
[41].
The function of ZAG is unknown but studies have shown
that it is present in several body fluids, including CSF,
sweat, saliva, seminal fluid, plasma, milk, amniotic fluid
and urine, suggesting a fairly widespread exocrine func-
tion of the protein [42]. In this study increased levels of
ZAG were found in FTD CSF and to our knowledge, ZAG
has not previously been associated with dementia.
The level of ProapoA1 was also increased in this study.
Our previous study of the FTD proteome [12] did not
show any increase in ProapoA1. Nevertheless, our study
of the AD proteome [11] detected reduced levels of 3 iso-
forms of ProapoA1.
The reason that several protein changes were inconsistent
between this and our previous study of the FTD proteome
may be explained by the fact that a smaller sample size
and a different population of FTD patients, which is a
rather heterogeneous disease, were used in this study. Due
to the small sample size it must also be emphasized that
the protein changes found in this study are preliminary.
Moreover, direct and prefractionated 2-DE are still two
different proteomic approaches and a somewhat different
analytical window was not unexpected. Indeed, direct and
prefractionated 2-D gels show different protein patterns,
for example, the apolipoprotein E and apolipoprotein J
isoforms seem to be missing in the prefractionated 2-D
gels, which may be explained by the fact that lipoproteins
tend to adhere to plastics [43] and could be lost during LP-
IEF or additional sample transfer steps in the prefraction-
ation procedure. However, the lipoprotein, ProapoA1
could still be detected in the prefractionated 2-D gels. The
proteins most likely to be favored by a prefractionation
step are low abundant hydrophilic proteins, which most
likely are present in CSF. Nevertheless, this investigation
of the FTD proteome failed to detect any very low abun-
dant brain specific proteins.
As shown in the present study, the levels of specific iso-
forms are altered and these are unlikely to be detected
using methods measuring the total concentration of a pro-
tein. Therefore, determination of posttranslational modi-
fications is of importance for understanding the
neuropathology in FTD, and 2-DE is a useful method for
sensitive detection of different protein isoforms.
Conclusions
We have shown that the prefractionated 2-DE method is
reproducible to the same extent as traditional 2-DE and
can enrich CSF proteins in the gel. This approach may
offer new perspectives on the pathology of neurodegener-
ative diseases. Prefractionated 2-DE analysis of FTD CSF
proteins confirmed some of the proteins previously
detected by direct 2-DE and revealed some new biomarker
candidates. The protein changes should be further
validated on a larger patient material, preferably also with
complementary methods, in order to assess any of the
proteins potential as biomarkers for FTD.
Methods
CSF samples
CSF samples were obtained from the Clinical Neurochem-
ical Laboratory (Sahlgrenska University Hospital/ Möl-
ndal). All CSF samples had a normal white-cell count,
normal blood-brain barrier function and absence of
intrathecal IgG and IgM production. The CSF samples for
the proteomic study, described in table 2, were obtained
from 5 FTD patients aged 70.6 ± 5.6 (mean ± SD) years
and 5 non-dementia controls aged 59.2 ± 11.9 years
(mean ± SD). FTD was diagnosed according to the Lund
Manchester criteria [4]. The severity of dementia was
evaluated using the Mini Mental State ExaminationProteome Science 2004, 2:7 http://www.proteomesci.com/content/2/1/7
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(MMSE) [44]. The control group, "non-demented con-
trols" consisted of subjects with minor psychiatric com-
plaints or subjective memory complaints that could not
be verified by clinical examination, CSF analysis or neu-
ropsychological testing. All control individuals had
MMSE scores of 29–30. Lumbar puncture was performed
in the L4–L5 vertebral interspace. The first 12 mL of CSF
was collected and gently mixed to avoid possible gradient
effects. The CSF samples were then centrifuged at 2,000 g
for 10 min to eliminate cells and other insoluble material,
and stored at -80°C.
The study was approved by the Ethical Committee of
Göteborg University. All participants or their relatives
gave their informed consent to participation in the study,
which was performed in accordance with the Declaration
of Helsinki.
Purification and precipitation methods
To find a method for effective reduction of impurities and
maximal protein recovery, 300 µL of prefractionated
pooled CSF samples (fraction 6–9, pH 4.5–6.0) were puri-
fied using each of the following methods:
1. Ice cold acetone precipitation; acetone: sample (4:1, v/v)
precipitated at -20°C for 2 hours.
2. Ice cold acetone-TCA precipitation; 2a) acetone: TCA: sam-
ple (4:10%:1, v/w/v) at -20°C for 45 min. 2b) acetone:
TCA: sample (4:20%:1, v/w/v) at -20°C for 45 min. The
protein pellet was washed 2 times with acetone after
centrifugation.
3.  Chloroform/methanol/water precipitation, chloroform:
methanol: sample (4:8:3, v/v/v) at room temperature for
2 hours.
4.  Ice cold ethanol precipitation; final concentrations of
60%, 70% and 80% ethanol was added to the sample and
precipitated for 2 hours at -20°C.
5. Purification using micro Bio-Spin column (Bio-Rad, Her-
cules, CA, USA) with a MW cut off of 6 kDa. The purifica-
tion procedure w two-dimensional electrophoresis (2-
DE) as performed according to the manufacturer's
instructions.
After precipitation all samples were centrifuged and the
protein pellet analyzed on 2-D gels, described below.
The protein recovery of acetone and ethanol treated sam-
ples was measured using the RC DC protein assay (Bio-
Rad) according to the manufacturer's instructions.
Prefractionation, sample preparation and 2-DE procedure
The CSF samples from individual patients were prefrac-
tionated using LP-IEF in the Rotofor cell (Bio-Rad). Three
mL CSF sample was mixed with 9 mL millipore water, 1%
ampholytes (Servalyte pH range 3–10, Serva Electro-
phoresis, GmbH, Germany), 20 mM dithiothreitol (DTT)
and 1 × Complete antiprotease solution (Roche Diagnos-
tics, Mannheim, Germany). The focusing was performed
at 4°C and at 12 W constant power for 2.5 hours. Then the
20 Rotofor fractions were harvested and fraction 2–5 cor-
responding to pH 1.5–4.5, fraction 6–9 corresponding to
pH 4.5–6.0 and fraction 10–14 corresponding to pH 6.0–
7.5 were pooled and concentrated to 300 µL in a vacuum
centrifuge prior to 2-DE.
In the FTD-study, the prefractionated pooled protein frac-
tions were precipitated using 900 µL 95 % ice-cold
ethanol (71.25% final conc. ethanol) for two hours at -
20°C. The mixture was centrifuged at 10,000 × g for 10
Table 2: CSF samples included in the prefractionated 2-DE study
Subject Agea) Sex Albumin ratiob) Tau (ng/L) Aβ (ng/L) MMSE
FTD 1 64 F 6.3 633 779 20
FTD 2 72 F 6.7 364 668 22
FTD 3 73 M 4.1 409 245 15
FTD 4 78 F 8.0 283 833 10
FTD 5 66 F 6.9 302 642 19
Control 1 63 M 6.7 368 599 29
Control 2 63 F 8.7 274 1070 30
Control 3 74 M 6.4 270 412 29
Control 4 54 F 5.5 210 1160 30
Control 5 42 M 2.8 318 1620 29
a) The age of the FTD group is 70.6 ± 5.6 years (mean ± SD) and the age of the control group is 59.2 ± 11.9 years (mean ± SD)
b) [CSF albumin(mg/L)] / [serum albumin(g/L)]Proteome Science 2004, 2:7 http://www.proteomesci.com/content/2/1/7
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min at 4°C. The protein pellets were air-dried and then
resolved in a buffer containing 9 M urea, 35 mM tris, 42
mM DTT, 2% 3-((3-cholamidopropyl)
dimethylammonio)-1-propanesulfonate (CHAPS),
0.66% sodium dodecyl sulfate (SDS), 2% IPG buffer and
bromophenol blue.
The first dimension was carried out using immobilized
pH gradient (IPG) strips (Bio-Rad), 7 cm, pH 3–6 for
Rotofor fractions 2–5, pH 4–7 for Rotofor fractions 6–9 or
pH 5–8 for Rotofor fractions 10–14. The IPG-strips were
actively rehydrated in the CSF-protein sample for 12 h at
50 V followed by protein focusing for 20,000 Vh using the
Protean IEF Cell (Bio-Rad). The IPG strips were placed in
5 ml equilibration solution (50 mM Tris-HCl pH 8.8, 6 M
urea, 30% glycerol, 2% SDS, bromophenol blue) contain-
ing 1% DTT, and 2.5% iodoacetamide in the second equi-
librium step for 2 × 15 min.
The second dimension was performed using the Nu-PAGE
gel system (NOVEX, San Diego, CA, USA) with (2-(N-
morpholino) ethane sulfonic acid (MES) buffer: 50 mM
MES, 50 mM tris, 3.5 mM SDS, 1 mM EDTA), for 35 min
at 200 V.
In the direct 2-DE procedure, 300 µL CSF proteins were
precipitated using 900 µL ice-cold acetone and stored for
two hours at -20°C. The mixture was then centrifuged at
10,000 × g for 10 min at 4°C. The 2-DE procedure was
performed as described above for prefractionated 2-DE.
Visualisation and evaluation
The gels were stained using SYPRO Ruby Protein Stain
(Molecular-Probes, Eugene, Oregon, USA) according to
the manufacturer's instructions. Image acquisition and
analysis were performed on a Fluor-S MultiImager (Bio-
Rad). The protein spots were detected, quantified and
matched with the PD-Quest 2-D gel analysis software,
v.7.0 (Bio-Rad). The gels were normalized according to
the total quantity in valid spots (the raw quantity of each
spot in a member gel is divided by the total quantity of all
the spots in that gel that have been included in the Master
gel). Protein levels increased or decreased two fold were
taken into account.
In-gel tryptic digestion and sample preparation
The protein digestion method has been previously
described in detail [11]. Briefly, the gel pieces were
digested with porcine trypsin (Promega Corporation,
Madison, USA) and the peptides were extracted with for-
mic acid (FA) and acetonitrile (ACN). The digested pro-
tein sample was dried under vacuum and then dissolved
in 10 µL 0.2% triflouroacetic acid (TFA) (v/v). The sam-
ples were applied to the MS probe using the AnchorChip™
technology (Bruker daltonics, Bremen, Germany) as pre-
viously described [45]. Briefly α-cyano-4-hydroxy-cin-
namic acid (CHCA) solution (100 g/L in 90% acetone,
0.005 % TFA) was spread out evenly on the sample plate
surface creating the CHCA matrix layer. Then 2µL of the
protein sample solution was applied to each anchor spot.
After 2 min, the remaining liquid was removed by absorp-
tion using a paper tissue.
Mass spectrometry and database searching
Matrix assisted laser desorption/ionization time-of-flight
(MALDI-TOF) MS analysis was performed using an
upgraded Reflex II MALDI-TOF MS (Bruker-Franzen Ana-
lytik GmbH, Bremen, Germany) equipped with a two-
stage electrostatic reflectron, a delayed extraction (time-
lag-focusing) ion source, a high resolution reflector detec-
tor and a 2 GHz digitizer. The spectra were acquired in the
reflection mode at an accelerating voltage of 20 kV. The
mass spectra, acquired and analyzed using Bruker soft-
ware, were initially calibrated by external calibration
using a mixture of known peptides and later recalibrated
using two auto digestion products of porcine trypsin as
internal calibrants. The protein database search tool
"MASCOT Peptide Mass Fingerprint" on the Matrix Sci-
ence web site [46] was used to compare the monoisotopic
m/z values of the tryptic fragments to those of known pro-
teins in the NCBI database. A mass deviation of 100 ppm
was tolerated and Homo sapiens was specified.
Statistical analysis
Coefficient of variation (CV) was calculated (standard
deviation (SD)/ Mean × 100) of the normalized protein
spot densities from four replicate 2-D gels.
In the proteomic study a 2-fold increase or decrease of
normalized protein quantities was taken into account.
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